OpenLB
Open Library of Bioscience
Advanced Search
Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents
Aug, 2013;22 (8): 3629-3639.

Antimicrobial and antiurease activities of newly synthesized morpholine derivatives containing an azole nucleus.

Hakan Bektaş, Sule Ceylan, Neslihan Demirbaş, Sengül Alpay-Karaoğlu, Bahar Bilgin Sökmen
Author Information
  1. Hakan Bektaş: Department of Chemistry, Faculty of Arts and Sciences, Giresun University, 28049 Giresun, Turkey.
PMID: 23807823 DOI: 10.1007/s00044-012-0318-1

Abstract

2-[6-(Morpholin-4-yl)pyridin-3-ylamino]acetohydrazide () was obtained starting from 6-morpholin-4-ylpyridin-3-amine () via the formation of ester () and then converted to the corresponding Schiff bases () with the reaction with aromatic aldehydes. The carbothioamide (), obtained from the reaction of hydrazide with phenylisothiocyanate, was converted to the corresponding 1,2,4-triazole () and 1,3,4-thiadiazole () derivatives by the treatment with NaOH or HSO, respectively. The cyclocondenzation of with 4-chlorophenacyl bromide or ethyl bromoacetate produced the corresponding 1,3-thiazole () or 1,3-thiazolidine derivatives (), respectively. Antimicrobial and antiurease activities of newly synthesized compounds were investigated. Some of them were found to be active on , and they displayed activity toward and in high concentration. Compound proved to be the most potent showing an enzyme inhibition activity with an IC = 2.37 ± 0.19 μM.

Keywords

1,2,4-Triazole 1,3,4-Oxadiazole Antimicrobial activity Antiurease activity Mannich base Morpholine

References

  1. Bioorg Med Chem. 2002 Jul;10(7):2345-51 [PMID: 11983532]
  2. Eur J Med Chem. 2009 Jul;44(7):2896-903 [PMID: 19167136]
  3. Lancet. 2006 Mar 18;367(9514):938-40 [PMID: 16546542]
  4. J Enzyme Inhib. 2001 Dec;16(6):507-16 [PMID: 12164390]
  5. Eur J Med Chem. 2010 Nov;45(11):5064-70 [PMID: 20801557]
  6. Eur J Med Chem. 2009 Mar;44(3):1057-66 [PMID: 18676062]
  7. J Pharm Biomed Anal. 2006 Jun 16;41(4):1146-51 [PMID: 16563688]
  8. Eur J Med Chem. 2007 Jun;42(6):851-60 [PMID: 17275965]
  9. Eur J Med Chem. 2007 Aug;42(8):1095-101 [PMID: 17346860]
  10. FEBS Lett. 2003 Dec 4;555(2):367-70 [PMID: 14644444]
  11. Eur J Med Chem. 2009 Oct;44(10):4148-52 [PMID: 19540629]
  12. Eur J Med Chem. 2009 Nov;44(11):4362-6 [PMID: 19647352]
  13. Bioorg Med Chem. 2008 Apr 1;16(7):3714-24 [PMID: 18299196]
  14. Eur J Med Chem. 2005 Feb;40(2):209-14 [PMID: 15694656]
  15. Curr Med Chem. 2002 Jul;9(14):1323-48 [PMID: 12132990]
  16. Eur J Med Chem. 2005 Dec;40(12):1351-8 [PMID: 16129517]
  17. Bioorg Chem. 2010 Jun;38(3):132-7 [PMID: 20202666]
  18. Bioorg Med Chem. 2004 May 1;12(9):2151-61 [PMID: 15080915]
  19. Planta Med. 2005 Mar;71(3):197-201 [PMID: 15770537]
  20. Biochem Biophys Res Commun. 2004 Jul 2;319(3):1053-63 [PMID: 15184088]
  21. Biochem Pharmacol. 1990 Aug 15;40(4):737-41 [PMID: 2167094]
  22. Clin Ther. 2007 Sep;29(9):1862-86 [PMID: 18035188]
  23. Eur J Med Chem. 2009 Oct;44(10):3954-60 [PMID: 19464085]
  24. Bioorg Med Chem. 2007 Dec 1;15(23):7281-7 [PMID: 17845853]
  25. Arzneimittelforschung. 1968 Jun;18(6):645-57 [PMID: 5755800]
  26. Eur J Med Chem. 2005 Feb;40(2):225-9 [PMID: 15694658]
  27. J Pharm Sci. 2007 Dec;96(12):3226-35 [PMID: 17518356]
  28. Bioorg Med Chem Lett. 2006 Feb;16(3):529-31 [PMID: 16275066]
  29. Bioorg Med Chem Lett. 2001 Jul 9;11(13):1793-6 [PMID: 11425562]
  30. Molecules. 2010 Apr 08;15(4):2427-38 [PMID: 20428053]
  31. Eur J Med Chem. 2006 Apr;41(4):519-25 [PMID: 16516352]
  32. Eur J Med Chem. 2010 Nov;45(11):5200-7 [PMID: 20828889]
  33. Biochem Biophys Res Commun. 2003 Oct 24;310(3):715-9 [PMID: 14550260]
  34. Eur J Pharmacol. 1998 Mar 19;345(2):193-8 [PMID: 9600637]
  35. Eur J Med Chem. 2002 Mar;37(3):197-206 [PMID: 11900864]
  36. J Enzyme Inhib Med Chem. 2009 Jun;24(3):898-902 [PMID: 18951285]
  37. Bioorg Med Chem Lett. 2000 Apr 17;10(8):715-7 [PMID: 10782671]
  38. Bioorg Med Chem Lett. 2005 Oct 1;15(19):4261-7 [PMID: 16054358]
  39. Arch Pharm (Weinheim). 2009 Aug;342(8):469-75 [PMID: 19565601]
  40. J Biochem Biophys Methods. 2007 Jan 10;69(3):251-9 [PMID: 16563516]
  41. Eur J Med Chem. 2006 Mar;41(3):423-8 [PMID: 16494970]
  42. Sci Transl Med. 2009 Oct 21;1(3):3ra8 [PMID: 20368167]
  43. J Agric Food Chem. 2008 May 28;56(10):3721-31 [PMID: 18452297]
  44. J Biotechnol. 2002 Feb 14;93(2):171-81 [PMID: 11738724]
  45. Bioorg Med Chem Lett. 2005 Jun 15;15(12):3002-5 [PMID: 15908210]
  46. Eur J Med Chem. 2010 Jul;45(7):3207-12 [PMID: 20381216]
  47. Eur J Med Chem. 2011 Nov;46(11):5473-9 [PMID: 21981981]
  48. J Mol Graph Model. 2010 Jun;28(8):792-8 [PMID: 20338793]
  49. Eur J Med Chem. 2010 Nov;45(11):4726-32 [PMID: 20727622]
  50. Eur J Med Chem. 2008 Apr;43(4):683-93 [PMID: 17611001]
Journal Article

Word Cloud

Created with Highcharts 10.0.01activitycorrespondingderivativesAntimicrobialobtainedconvertedreaction23respectivelyantiureaseactivitiesnewlysynthesized2-[6-Morpholin-4-ylpyridin-3-ylamino]acetohydrazidestarting6-morpholin-4-ylpyridin-3-amineviaformationesterSchiffbasesaromaticaldehydescarbothioamidehydrazidephenylisothiocyanate4-triazole4-thiadiazoletreatmentNaOHHSOcyclocondenzation4-chlorophenacylbromideethylbromoacetateproduced3-thiazole3-thiazolidinecompoundsinvestigatedfoundactivedisplayedtowardhighconcentrationCompoundprovedpotentshowingenzymeinhibitionIC = 237 ± 019 μMmorpholinecontainingazolenucleus4-Triazole4-OxadiazoleAntiureaseMannichbaseMorpholine

Similar Articles

Cited By